Peer-Reviewed Study Confirms Targeted Laser Therapy Success in Mycosis Fungoides Subtype
STRATA Skin Sciences (NASDAQ:SSKN) has just achieved a pivotal milestone with a newly published, peer-reviewed study confirming that its XTRAC 308-nm excimer laser can effectively treat a rare, stubborn form of cutaneous T-cell lymphoma: poikilodermatous mycosis fungoides (pMF). The study—led by Tohoku University researchers in Japan and published in Case Reports in Oncology—represents the first English-language clinical documentation of successful excimer laser use in this hard-to-treat cancer variant.
Study Details: Complete Clinical Resolution Observed After Laser Therapy
In the featured case, a 50-year-old woman with a three-year history of worsening lesions unresponsive to traditional therapies achieved full clinical resolution after only five excimer laser sessions paired with topical steroids. Within three months, symptoms—including erythema and pigmentation—markedly improved, spotlighting the laser’s power in targeted treatment where whole-body phototherapies often fail.
Meta-Analysis: Excimer Laser Delivers 73.6% Complete Response Rate
Looking beyond the individual case, a systematic review published in 2022 aggregated 14 studies involving 72 mycosis fungoides patients. On average, 73.6% achieved a complete clinical response, while only 2.8% showed no improvement. Importantly, relapses occurred in just 5.7% of complete responders after a year, and side effects were mild and transient. The data positions excimer laser therapy as both effective and safe for localized early-stage disease, achieving durable remission rates with low toxicity risks.
| Treatment Type | Number of Studies | Number of Patients | Complete Response | Partial Response | No Improvement | Relapse Rate |
|---|---|---|---|---|---|---|
| 308-nm Excimer Laser | 14 | 72 | 73.6% | 22.2% | 2.8% | 5.7% (mean 13 months) |
Laser Therapy Offers a Safer, More Targeted Approach Than Standard Treatments
Traditional whole-body phototherapy, such as narrowband UVB or PUVA, carries cumulative exposure risks and lacks lesion specificity. By comparison, excimer laser delivers concentrated, lesion-focused energy, minimizing systemic toxicity while improving response in tough-to-treat or thickened lesions. This makes excimer lasers especially promising for patients who may not tolerate or respond to existing therapies.
Expanded Market and Regulatory Opportunity Backed by Strong Clinical Momentum
The significance of these results is magnified by recent CMS reimbursement code expansions for XTRAC laser indications, opening the door to broader patient access. According to Dr. Dolev Rafaeli, STRATA’s CEO, ongoing real-world validation by independent investigators worldwide reinforces confidence in XTRAC’s clinical utility for a growing list of autoimmune and rare skin diseases—including in major markets like Japan.
Broader Impact: Improving Care for a Rare and Underdiagnosed Cancer
Mycosis fungoides, a rare cutaneous lymphoma, sees just 4–6 new cases per million people per year in the US. Early diagnosis and new treatments like excimer laser could dramatically improve quality of life for patients facing persistent, visible skin lesions with limited traditional options. The XTRAC excimer laser stands out as a technology that may shape the next era of skin lymphoma care.
What’s Next for SSKN Investors?
For investors and practitioners, the takeaway is clear: robust peer-reviewed evidence, expanding insurance coverage, and positive patient outcomes set STRATA Skin Sciences apart in the dermatologic technology landscape. The continued validation and adoption of XTRAC could lead to wider use, deeper clinical guidelines integration, and possibly improved revenue opportunities as the company continues to work closely with regulators and expand its global footprint.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI